155 related articles for article (PubMed ID: 16769957)
1. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
Lorenz D; Hagen K; Ufer M; Cascorbi I; Deuschl G; Volkmann J
Neurology; 2006 Jun; 66(11):1753-5. PubMed ID: 16769957
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
Kalla R; Spiegel R; Claassen J; Bardins S; Hahn A; Schneider E; Rettinger N; Glasauer S; Brandt T; Strupp M
J Neuroophthalmol; 2011 Dec; 31(4):320-5. PubMed ID: 21734596
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.
Pahwa R; Lyons KE
Mov Disord; 2003 May; 18(5):584-7. PubMed ID: 12722174
[TBL] [Abstract][Full Text] [Related]
4. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.
Zesiewicz TA; Ward CL; Hauser RA; Sanchez-Ramos J; Staffetti JF; Sullivan KL
Mov Disord; 2007 Jan; 22(2):279-82. PubMed ID: 17149715
[TBL] [Abstract][Full Text] [Related]
5. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor.
Handforth A; Martin FC
Mov Disord; 2004 Oct; 19(10):1215-21. PubMed ID: 15390011
[TBL] [Abstract][Full Text] [Related]
6. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
[TBL] [Abstract][Full Text] [Related]
8. Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.
Gironell A; Kulisevsky J; Pascual-Sedano B; Flamarich D
Mov Disord; 2006 Apr; 21(4):441-5. PubMed ID: 16229019
[TBL] [Abstract][Full Text] [Related]
9. Carisbamate in essential tremor: brief report of a proof of concept study.
Elble RJ; Biondi DM; Ascher S; Wiegand F; Hulihan J
Mov Disord; 2010 Apr; 25(5):634-8. PubMed ID: 20201005
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam is not effective for essential tremor.
Elble RJ; Lyons KE; Pahwa R
Clin Neuropharmacol; 2007; 30(6):350-6. PubMed ID: 18090460
[TBL] [Abstract][Full Text] [Related]
11. The effect of levetiracetam on essential tremor.
Bushara KO; Malik T; Exconde RE
Neurology; 2005 Mar; 64(6):1078-80. PubMed ID: 15781835
[TBL] [Abstract][Full Text] [Related]
12. Zonisamide for essential tremor: an evaluator-blinded study.
Handforth A; Martin FC; Kang GA; Vanek Z
Mov Disord; 2009 Feb; 24(3):437-40. PubMed ID: 19117357
[TBL] [Abstract][Full Text] [Related]
13. Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
Bertorini TE; Rashed H; Zeno M; Tolley EA; Igarashi M; Li YD
J Clin Neuromuscul Dis; 2011 Mar; 12(3):129-37. PubMed ID: 21321491
[TBL] [Abstract][Full Text] [Related]
14. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
[TBL] [Abstract][Full Text] [Related]
15. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Strupp M; Schüler O; Krafczyk S; Jahn K; Schautzer F; Büttner U; Brandt T
Neurology; 2003 Jul; 61(2):165-70. PubMed ID: 12874393
[TBL] [Abstract][Full Text] [Related]
16. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
[TBL] [Abstract][Full Text] [Related]
17. Effect of ethanol on the central oscillator in essential tremor.
Zeuner KE; Molloy FM; Shoge RO; Goldstein SR; Wesley R; Hallett M
Mov Disord; 2003 Nov; 18(11):1280-5. PubMed ID: 14639668
[TBL] [Abstract][Full Text] [Related]
18. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
Sprenger A; Zils E; Rambold H; Sander T; Helmchen C
Ann N Y Acad Sci; 2005 Apr; 1039():395-403. PubMed ID: 15826992
[TBL] [Abstract][Full Text] [Related]
19. Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid).
Melmed C; Moros D; Rutman H
Mov Disord; 2007 Apr; 22(5):723-7. PubMed ID: 17265458
[TBL] [Abstract][Full Text] [Related]
20. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
Tsunemi T; Ishikawa K; Tsukui K; Sumi T; Kitamura K; Mizusawa H
J Neurol Sci; 2010 May; 292(1-2):81-4. PubMed ID: 20181362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
